Health Care | Pharmaceuticals, Biotechnology & Life Sciences | Biotechnology
NASDAQ | Common Stock
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer.
Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer.
The company is also developing programs targeting FGFR2-related cancers, FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers.
Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jun 30, 21 | -2.43 Decreased by -91.30% | - |
| Mar 31, 21 | -2.09 Decreased by -96.32% | - |
| Dec 31, 20 | -1.80 | - |
| Sep 30, 20 | -1.80 | - |
| Jun 30, 20 | -1.27 | - |
| Mar 31, 20 | -1.07 | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 21 | N/A - | N/A - | - - |
| Mar 31, 21 | N/A - | N/A - | - - |
| Dec 31, 20 | N/A - | N/A - | - - |
| Sep 30, 20 | N/A - | N/A - | - - |